Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1 1

Status

Completed 3Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5Thoracic 1Gastrointestinal 1

Conditions

Neoplasms 9Ovarian Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Multiple Myeloma 2Stomach Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms by Site 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Colorectal Neoplasms 1Bites and Stings 1Adenocarcinoma 1

Interventions

Paclitaxel 96Carboplatin 81Bevacizumab 62Gemcitabine 36liposomal doxorubicin 32pembrolizumab 30Topotecan 26olaparib 23Taxes 23niraparib 17Immunoglobulin G 17Disulfides 17Docetaxel 16Cyclophosphamide 16Cisplatin 14Nivolumab 11rucaparib 10durvalumab 10Doxorubicin 9Albumin-Bound Paclitaxel 8sargramostim 7pazopanib 7fludarabine phosphate 7fludarabine 7avelumab 7Magnetic Resonance Spectroscopy 7Ifosfamide 7epacadostat 6Trabectedin 6Sorafenib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Ovarian Neoplasms × dostarlimab × Clear all
NCT03602859 2025-12-31

FIRST

Tesaro, Inc.

Phase 3 Active not recruiting
1,400 enrolled 18 charts
Gynecologic

Ovarian Neoplasms

NCT03574779 2025-07-15

OPAL

Tesaro, Inc.

Phase 2 Completed
77 enrolled 8 charts
Gynecologic

Ovarian Neoplasms

NCT03250832 2024-04-11

CITRINO

Tesaro, Inc.

Phase 1 Completed
111 enrolled 48 charts
GastrointestinalGynecologicThoracic

Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT05751629 2023-04-21

COHORT-A

Tesaro, Inc.

Phase 2 Completed
41 enrolled 17 charts
Gynecologic

Ovarian Neoplasms

NCT03955471 2022-09-10

MOONSTONE

Tesaro, Inc.

Phase 2 Terminated
41 enrolled 22 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡